ClinicalTrials.Veeva

Menu

The Short-term Efficacy of Novel NTDP-RFA in the Treatment of Small HCC With Cirrhosis.

A

Army Medical University

Status

Unknown

Conditions

Hepatocellular Carcinoma Stage I
Radiofrequency Ablation

Study type

Observational

Funder types

Other

Identifiers

NCT04513119
cstc2019jscx-msxmX0230

Details and patient eligibility

About

To evaluate the short-term efficacy of novel no-touch combined directional perfusion radiofrequency ablation in the treatment of small hepatocellular carcinoma with cirrhosis.

Full description

Liver cancer is the fourth leading cause of cancer-related deaths globally. Hepatocellular carcinoma (HCC) accounts for 70% to 85% of primary HCC and is the leading cause of death in patients with cirrhosis. We developed a novel no-touch combined directional perfusion radiofrequency ablation system.By inserting two or more electrodes around the tumor and activating them simultaneously.The hypertonic saline solution can be directed into the focal tissue from a lateral pore through a tube within the electrode to provide more uniform and thorough necrosis.The maximum ablation volume was increased while the loss of normal tissue in the non-injection direction was reduced, thus reducing the incidence of postoperative complications. Therefore, the purpose of this study was to evaluate the short-term efficacy of novel no-touch combined directional perfusion radiofrequency ablation in the treatment of small hepatocellular carcinoma with cirrhosis.

Enrollment

100 estimated patients

Sex

All

Ages

18 to 70 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Primary hepatocellular carcinoma with a background of cirrhosis
  • Single shot with diameter ≤ 3cm
  • The tumor did not invade portal vein, hepatic vein trunk and secondary branches
  • Child Pugh A/B
  • ICG-R15 ≤ 30%
  • 18-70 years old
  • The follow-up time reached 2 years

Exclusion criteria

  • The follow-up time is less than 2 years
  • multiple lesions or diameter > 3cm
  • Previous history of upper gastrointestinal bleeding or severe hypersplenism
  • Patients with extrahepatic or lymph node metastasis
  • Wish to receive liver transplantation and hepatectomy
  • The lesion is adjacent to the gallbladder, important blood vessels and bile ducts in the hilum of the liver and important organs around
  • severe bleeding tendency, platelet count < 50 × 10^9/L, or prothrombin time prolonged > 3s
  • Other anti-tumor therapies were accepted before surgery

Trial contacts and locations

1

Loading...

Central trial contact

Kai Feng, M.D

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems